PT2908805T - Formulações de levodopa para alívio rápido da doença de parkinson - Google Patents

Formulações de levodopa para alívio rápido da doença de parkinson

Info

Publication number
PT2908805T
PT2908805T PT138493887T PT13849388T PT2908805T PT 2908805 T PT2908805 T PT 2908805T PT 138493887 T PT138493887 T PT 138493887T PT 13849388 T PT13849388 T PT 13849388T PT 2908805 T PT2908805 T PT 2908805T
Authority
PT
Portugal
Prior art keywords
parkinson
disease
rapid relief
levodopa formulations
levodopa
Prior art date
Application number
PT138493887T
Other languages
English (en)
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of PT2908805T publication Critical patent/PT2908805T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT138493887T 2012-10-22 2013-10-21 Formulações de levodopa para alívio rápido da doença de parkinson PT2908805T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716740P 2012-10-22 2012-10-22
US201361813605P 2013-04-18 2013-04-18
US201361813725P 2013-04-19 2013-04-19

Publications (1)

Publication Number Publication Date
PT2908805T true PT2908805T (pt) 2021-09-10

Family

ID=50545142

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138493887T PT2908805T (pt) 2012-10-22 2013-10-21 Formulações de levodopa para alívio rápido da doença de parkinson

Country Status (18)

Country Link
US (2) US20150328175A1 (pt)
EP (2) EP2908805B1 (pt)
JP (2) JP2016500690A (pt)
KR (2) KR20150102960A (pt)
CN (2) CN110812350A (pt)
AU (3) AU2013334949B2 (pt)
BR (1) BR112015009088A2 (pt)
CA (1) CA2888994C (pt)
DK (1) DK2908805T3 (pt)
ES (1) ES2886529T3 (pt)
HK (1) HK1212623A1 (pt)
MX (3) MX372641B (pt)
NZ (1) NZ708414A (pt)
PL (1) PL2908805T3 (pt)
PT (1) PT2908805T (pt)
RU (2) RU2685718C2 (pt)
SG (2) SG11201503129RA (pt)
WO (1) WO2014066208A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102237007B1 (ko) * 2012-10-22 2021-04-06 키비타스 테라퓨틱스, 인코포레이티드. 레보도파 혈장 농도의 환자간 변산도의 감소
PT2908805T (pt) 2012-10-22 2021-09-10 Civitas Therapeutics Inc Formulações de levodopa para alívio rápido da doença de parkinson
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2015163840A1 (en) * 2014-04-21 2015-10-29 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
EP3735298A4 (en) * 2018-01-05 2021-10-06 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF LEVODOPA POWDER BY N BY AN OLFACTORIC PRECISION DEVICE
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
JP4384503B2 (ja) 2002-03-20 2009-12-16 アルカーメス,インコーポレイテッド レボドパの肺送達
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
EP2320892A2 (en) 2008-06-30 2011-05-18 Novartis AG Combination products
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
KR102237007B1 (ko) 2012-10-22 2021-04-06 키비타스 테라퓨틱스, 인코포레이티드. 레보도파 혈장 농도의 환자간 변산도의 감소
PT2908805T (pt) 2012-10-22 2021-09-10 Civitas Therapeutics Inc Formulações de levodopa para alívio rápido da doença de parkinson
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US8545878B1 (en) 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
CN104884046A (zh) 2015-09-02
MX2015005038A (es) 2015-12-01
PL2908805T3 (pl) 2021-12-27
EP2908805A4 (en) 2016-07-06
US20250248960A1 (en) 2025-08-07
SG11201503129RA (en) 2015-05-28
CA2888994A1 (en) 2014-05-01
MX372641B (es) 2020-06-15
MX2021014782A (es) 2023-03-23
US12458615B2 (en) 2025-11-04
JP2018150339A (ja) 2018-09-27
AU2018253538B2 (en) 2020-08-20
JP2016500690A (ja) 2016-01-14
AU2020250325A1 (en) 2020-11-12
BR112015009088A2 (pt) 2017-07-04
NZ708414A (en) 2018-11-30
HK1212623A1 (zh) 2016-06-17
RU2685718C2 (ru) 2019-04-23
AU2013334949A1 (en) 2015-06-11
AU2013334949B2 (en) 2018-08-09
EP2908805A1 (en) 2015-08-26
DK2908805T3 (da) 2021-09-13
ES2886529T3 (es) 2021-12-20
US20150328175A1 (en) 2015-11-19
RU2015119377A (ru) 2016-12-10
KR20150102960A (ko) 2015-09-09
MX390106B (es) 2025-03-20
CN110812350A (zh) 2020-02-21
WO2014066208A1 (en) 2014-05-01
SG10201804985QA (en) 2018-07-30
AU2018253538A1 (en) 2018-11-22
EP3943080A1 (en) 2022-01-26
HK1212258A1 (zh) 2016-06-10
EP2908805B1 (en) 2021-06-09
RU2019111096A (ru) 2020-10-12
CA2888994C (en) 2022-10-04
KR20210075224A (ko) 2021-06-22

Similar Documents

Publication Publication Date Title
IL266648B (en) A method for treating Parkinson's disease
ES2892029T5 (en) Formulations of enzalutamide
ZA201406916B (en) New therapeutic approaches for treating parkinson's disease
SMT201800678T1 (it) Composizioni farmaceutiche per il trattamento del morbo di alzheimer
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
IL230441A0 (en) Diagnosis of Alzheimer's disease
GB201206382D0 (en) Parkinson's disease biomarker
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
SG11201503129RA (en) Levodopa formulations for rapid relief of parkinson's disease
IL233572B (en) A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease
SG11201405279TA (en) Composition for enhancing defenses of skin
PL2730279T3 (pl) Preparaty cynakalcetu o natychmiastowym uwalnianiu
TWI560195B (en) Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
PL120295U1 (pl) Korpus pluga
HK1230665A1 (en) Mirnas as non-invasive biomarkers for parkinson's disease
IL241482B (en) A method for treating Parkinson's disease
GB201205857D0 (en) Skin care formulations
GB201214450D0 (en) Huntington's disease
GB201103769D0 (en) Cosmetic formulations
GB201103767D0 (en) Cosmetic formulations
GB201204645D0 (en) Treatment of disease
GB201013824D0 (en) Ophthalmic formulations